rec7 Antibody

What is Rec7 and why is it significant in research?

Rec7 is a 249-amino acid protein encoded by the rec7 gene in Schizosaccharomyces pombe (fission yeast). It is specifically expressed during meiosis and is required for meiotic intragenic recombination but not for mitotic recombination . The significance of Rec7 lies in its critical role in the early steps of meiotic recombination, as evidenced by its expression pattern, which peaks at 2-3 hours after meiotic induction and then disappears by 4 hours . Studying Rec7 can provide valuable insights into the mechanisms of meiotic recombination, chromosome pairing, and ultimately, genome stability and evolution.

What types of antibodies against Rec7 are currently available for research?

While the search results don't specifically mention commercially available Rec7 antibodies, researchers typically have access to several types of antibodies for studying proteins like Rec7. These include:

• Polyclonal antibodies - Generated by immunizing animals with synthetic peptides corresponding to portions of the Rec7 protein, similar to how polyclonal antibodies against other proteins are produced .

• Monoclonal antibodies - Produced using hybridoma technology to ensure specificity against particular Rec7 epitopes, following approaches similar to those used for antibodies like RECK (D8C7) Rabbit mAb .

• Recombinant antibodies - Engineered using molecular biology techniques to enhance specificity and reduce cross-reactivity with related proteins.

How can I verify the specificity of a Rec7 antibody?

Verifying antibody specificity is crucial for experimental validity. For Rec7 antibodies, consider these methodological approaches:

• Western blotting validation: Compare wild-type S. pombe strains with rec7 deletion mutants. A specific Rec7 antibody should detect a band at approximately 27-30 kDa (based on 249 amino acids) in wild-type cells during meiosis but not in deletion mutants or during mitotic growth .

• Immunoprecipitation followed by mass spectrometry: This approach can confirm that the antibody is capturing the intended Rec7 protein.

• Immunofluorescence comparison: Staining patterns should be absent in rec7 deletion strains and should follow the expected temporal pattern (appearing 2-3 hours after meiotic induction and disappearing by 4 hours) .

• Cross-reactivity testing: Test against related proteins or in species with known homologs to ensure specificity, similar to how species cross-reactivity is assessed for other antibodies .

How can Rec7 antibodies be optimized for chromatin immunoprecipitation (ChIP) experiments?

Optimizing Rec7 antibodies for ChIP requires careful consideration of several factors:

• Fixation conditions: Since Rec7 interacts with DNA during meiotic recombination, optimize crosslinking times (typically 10-15 minutes with 1% formaldehyde) to preserve protein-DNA interactions without over-crosslinking.

• Sonication parameters: Adjust sonication conditions to generate DNA fragments of 200-500 bp for optimal resolution of Rec7 binding sites.

• Antibody validation for ChIP: Perform preliminary ChIP-qPCR targeting known recombination hotspots in S. pombe before proceeding to genome-wide approaches.

• Controls: Include both technical controls (IgG) and biological controls (rec7 deletion strains) to distinguish specific from non-specific signals.

• Sequential ChIP: Consider sequential ChIP (ChIP-reChIP) to investigate Rec7 co-localization with other recombination proteins, using methods similar to those applied in other protein interaction studies .

What are the best approaches for detecting temporal changes in Rec7 localization during meiosis?

Given that Rec7 expression is tightly regulated during meiosis , capturing its dynamic localization requires:

• Synchronization methods: Use temperature-sensitive pat1 mutants or nitrogen starvation protocols to achieve highly synchronized meiotic cultures in S. pombe.

• Time-course sampling: Collect samples at 30-minute intervals from 0-6 hours after meiotic induction, focusing particularly on the 1-4 hour window when Rec7 expression peaks .

• Immunofluorescence optimization: For fixed cells, test different fixation methods (methanol vs. formaldehyde) to preserve epitope accessibility while maintaining nuclear architecture.

• Live-cell imaging: For dynamic studies, consider creating functional fluorescent protein-tagged Rec7 constructs (verified by complementation assays) to track localization in real-time.

• Co-localization analysis: Use multiple fluorescent channels to simultaneously track Rec7 alongside chromosomal landmarks (e.g., centromeres, telomeres) and other recombination proteins.

How can contradictory Rec7 antibody data be reconciled in research findings?

When facing contradictory results with Rec7 antibodies, consider these analytical approaches:

• Epitope accessibility issues: Different antibodies may target distinct Rec7 epitopes that become masked during specific protein interactions or conformational changes. Test multiple antibodies targeting different regions of Rec7.

• Post-translational modifications: Rec7 may undergo phosphorylation or other modifications during meiosis that affect antibody recognition. Use phospho-specific antibodies or treat samples with phosphatases to test this hypothesis.

• Protein complex formation: Rec7 likely functions within protein complexes that might obscure antibody binding sites. Use different extraction conditions or native versus denaturing conditions to address this.

• Technical variation: Standardize protocols across laboratories, including fixation times, antibody concentrations, and incubation conditions to minimize technical variability.

• Genetic background effects: Different S. pombe strains may show subtle variations in Rec7 expression or function. Verify results across multiple well-characterized strain backgrounds.

What are the recommended protocols for generating custom Rec7 antibodies?

For researchers needing to generate custom Rec7 antibodies, follow these methodological guidelines:

• Antigen design: Based on the 249-amino acid sequence of Rec7 , select 2-3 peptide regions that:

  • Are predicted to be surface-exposed

  • Have high antigenicity scores

  • Avoid regions with high sequence conservation to related proteins

  • Target approximately 15-20 amino acid sequences

• Immunization strategy:

  • For polyclonal antibodies: Immunize rabbits with KLH-conjugated peptides using a standard 84-day protocol with at least 4 immunizations

  • For monoclonal antibodies: Consider immunizing mice or rats following protocols similar to those used for other research antibodies

• Purification approaches:

  • Affinity purification against the immunizing peptide is essential

  • Consider negative selection against related proteins if cross-reactivity is observed

• Validation requirements:

  • Western blot against recombinant Rec7 protein

  • Immunoprecipitation efficiency testing

  • Testing in both mitotic and meiotic S. pombe extracts (expression should only be detected in meiosis)

  • Testing in rec7 deletion strains (no signal should be detected)

What are the critical factors affecting the success of Rec7 immunoprecipitation experiments?

Successful immunoprecipitation of Rec7 requires optimizing several parameters:

Additionally, consider these factors:

• Crosslinking: For detecting transient interactions, use reversible crosslinkers like DSP (dithiobis(succinimidyl propionate)).

• Bead selection: Compare protein A/G beads vs. directly conjugated antibody beads for optimal recovery.

• Pre-clearing: Always pre-clear lysates with beads alone to reduce background.

• Controls: Include both IgG controls and immunoprecipitation from rec7 deletion strains.

How should Rec7 antibodies be stored and handled to maintain long-term activity?

Proper storage and handling of Rec7 antibodies is critical for maintaining their performance over time:

• Stock storage conditions:

  • Store concentrated antibody (>0.5 mg/ml) at -80°C in small aliquots to avoid freeze-thaw cycles

  • For working solutions, store at 4°C with preservatives such as 0.02% sodium azide

  • Follow manufacturer guidelines for specific storage recommendations

• Freeze-thaw management:

  • Limit freeze-thaw cycles to ≤5 total

  • Thaw antibodies slowly on ice rather than at room temperature

  • Consider adding stabilizing proteins (BSA 1-5%) for dilute solutions

• Contamination prevention:

  • Use sterile technique when handling antibody solutions

  • Filter sterilize buffers used for antibody dilution

  • Include antimicrobial agents in long-term storage solutions

• Periodic validation:

  • Test antibody performance every 6-12 months using standardized positive controls

  • Monitor for changes in background signal or specific band intensity

  • Document lot-to-lot variation if using commercial antibodies

• Optimization for different applications:

  • Determine if different storage conditions are needed for specific applications (e.g., ChIP vs. Western blotting)

  • Consider adding glycerol (30-50%) for antibodies used in applications sensitive to sodium azide

How can non-specific binding be minimized when using Rec7 antibodies?

Reducing non-specific binding requires systematic optimization:

• Blocking optimization:

  • Test different blocking agents (BSA, milk, serum, commercial blockers)

  • Extend blocking time to 2 hours at room temperature or overnight at 4°C

  • Include 0.1-0.3% Tween-20 in washing and incubation buffers

• Antibody dilution titration:

  • Perform systematic dilution series to identify optimal concentration

  • Consider using antibody concentrations similar to those recommended for other nuclear proteins

  • Balance signal strength against background

• Pre-adsorption techniques:

  • Pre-incubate antibody with lysates from rec7 deletion strains

  • Use extracts from mitotic cells (where Rec7 is not expressed) to pre-adsorb antibodies

• Washing optimization:

  • Increase number of washes (5-6 washes)

  • Use buffers with increasing stringency (higher salt, detergent)

  • Extend wash durations to 10-15 minutes each

• Secondary antibody considerations:

  • Use highly cross-adsorbed secondary antibodies

  • Test multiple secondary antibody sources if background persists

  • Consider directly conjugated primary antibodies to eliminate secondary antibody issues

What approaches can address weak or absent signals when detecting Rec7?

When facing weak or absent signals when detecting Rec7, consider these methodological solutions:

• Timing optimization:

  • Ensure samples are collected during peak Rec7 expression (2-3 hours after meiotic induction)

  • Verify synchronization efficiency using known meiotic markers

• Protein extraction optimization:

  • Test harsher extraction conditions (higher detergent, sonication)

  • Use specialized nuclear extraction protocols to enrich for chromatin-bound proteins

  • Consider adding phosphatase inhibitors if Rec7 is phosphorylated during meiosis

• Signal amplification methods:

  • Employ tyramide signal amplification for immunofluorescence

  • Use biotin-streptavidin systems for Western blotting

  • Consider super-sensitive ECL substrates for chemiluminescent detection

• Sample preparation improvements:

  • Increase protein loading (50-100 μg for Western blots)

  • Use gradient gels to improve separation of proteins in the 25-35 kDa range

  • Optimize transfer conditions for proteins of this size range

• Epitope retrieval:

  • For fixed samples, test antigen retrieval methods (heat, pH, enzymatic)

  • For Western blots, ensure complete denaturation (boil samples in SDS sample buffer containing reducing agents)

How can researchers distinguish between specific and non-specific bands in Western blots using Rec7 antibodies?

Distinguishing specific from non-specific signals requires multiple controls and analytical approaches:

• Essential controls:

  • rec7 deletion strains (specific band should be absent)

  • Mitotic vs. meiotic samples (Rec7 is only expressed during meiosis)

  • Peptide competition (pre-incubating antibody with immunizing peptide should eliminate specific bands)

• Size verification:

  • Based on the 249-amino acid sequence, Rec7 has a predicted molecular weight of approximately 27-30 kDa

  • Consider potential post-translational modifications that might alter migration

  • Compare to size markers and recombinant Rec7 protein controls

• Expression pattern analysis:

  • Track temporal expression during meiosis time course

  • Specific Rec7 bands should follow the known expression pattern (appearing at 2-3 hours, gone by 4 hours)

  • Non-specific bands typically don't show this regulated pattern

• Multiple antibody validation:

  • Compare results using antibodies raised against different Rec7 epitopes

  • Specific bands should be detected by multiple independent antibodies

  • Pattern of non-specific bands will typically differ between antibodies

• Mass spectrometry confirmation:

  • For definitive identification, excise the band and perform mass spectrometry

  • Compare peptide coverage to the known Rec7 sequence

  • Quantify confidence scores for protein identification

How can Rec7 antibodies be used to study protein-protein interactions in the meiotic recombination complex?

Investigating Rec7's interactions requires specialized immunological approaches:

• Co-immunoprecipitation strategies:

  • Optimize lysis conditions to preserve native protein complexes

  • Use reversible crosslinkers to capture transient interactions

  • Perform reciprocal IPs with antibodies against known recombination proteins

  • Analyze by Western blot or mass spectrometry for comprehensive interaction mapping

• Proximity ligation assays (PLA):

  • Combine Rec7 antibodies with antibodies against potential interacting partners

  • PLA provides in situ visualization of proteins within 40 nm proximity

  • Quantify interaction signals throughout meiotic progression

• FRET/FLIM approaches:

  • Use fluorophore-conjugated antibodies against Rec7 and partner proteins

  • Measure energy transfer as evidence of close molecular association

  • This approach can work in fixed cells when suitable antibodies are available

• Sequential ChIP (ChIP-reChIP):

  • First IP with Rec7 antibody, then release and perform second IP with antibody against potential partner

  • This approach identifies genomic loci where both proteins co-localize

  • Compare to single ChIP data to identify collaborative binding sites

• BioID or APEX proximity labeling:

  • Create fusion proteins with biotin ligase or peroxidase

  • Use antibodies to validate proximity labeling results

  • This approach can identify both stable and transient interaction partners

What are the considerations for using Rec7 antibodies in different model organisms?

When extending Rec7 research beyond S. pombe, consider these cross-species approaches:

• Homology analysis:

  • Rec7 has functional homologs in other organisms (e.g., Rec114 in S. cerevisiae)

  • Perform sequence alignments to identify conserved epitopes

  • Test cross-reactivity systematically against extracts from different species

• Validation requirements:

  • For each new species, perform complete validation (Western blot, IP, immunofluorescence)

  • Compare expression patterns and localization to known Rec7 biology

  • Verify specificity using genetic knockouts or RNAi when available

• Epitope conservation assessment:

  • Design custom antibodies against highly conserved regions for cross-species applications

  • Consider using multiple antibodies targeting different regions to maximize detection probability

  • Test synthetic peptides from different species for antibody binding efficiency

• Application-specific optimization:

  • Different species may require different sample preparation methods

  • Adjust protocols for tissue-specific or developmental stage-specific expression

  • Modify fixation and permeabilization protocols based on cellular architecture

• Control considerations:

  • Include both positive controls (S. pombe extracts) and negative controls (pre-immune serum)

  • Use appropriate genetic models (knockouts, tagged versions) in each species

  • Document species-specific background patterns for accurate interpretation

How might emerging antibody technologies enhance Rec7 research in the future?

Emerging technologies offer new possibilities for studying Rec7:

• Single-domain antibodies (nanobodies):

  • Smaller size allows better penetration in intact cells and tissues

  • Potential for improved access to sterically hindered epitopes in Rec7 complexes

  • Can be expressed intracellularly to track Rec7 in living cells during meiosis

• Recombinant antibody engineering:

  • Custom design antibodies with optimized affinity and specificity for Rec7

  • Develop bispecific antibodies to simultaneously target Rec7 and interacting partners

  • Engineer antibodies with site-specific conjugation for precise labeling

• Antibody-based biosensors:

  • Design conformational sensors to detect Rec7 activation states

  • Develop FRET-based reporters using antibody fragments

  • Create optogenetic tools combined with antibody recognition domains

• Spatially-resolved antibody techniques:

  • Apply multiplexed ion beam imaging or CODEX for highly multiplexed protein detection

  • Use DNA-barcoded antibodies for spatial transcriptomics combined with protein detection

  • Implement expansion microscopy with Rec7 antibodies for super-resolution imaging

• Cryo-EM applications:

  • Use antibody fragments to stabilize Rec7 complexes for structural studies

  • Develop recombinant antibodies specifically designed to facilitate crystallization

  • Apply correlative light and electron microscopy with immunogold labeling